CP1-1189

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H18N2O2
Molecular Weight	234.2942
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C

InChI

InChIKey=DJKNRCWSXSZACF-UHFFFAOYSA-N

InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12451199 | https://www.pharmacodia.com/web/drug/1_5682.html | https://www.ncbi.nlm.nih.gov/pubmed/11175320

CPI-1189 is a synthetic benzamide with antioxidant properties that blocks tumor necrosis factor-alpha (TNFalpha) effects in animal models. It has neuroprotective properties in model systems for HIV-associated neurotoxicity and thus is a candidate for neuroprotective therapy in humans with HIV-associated CNS disease. CPI-1189 was at the phase II stage of clinical development for the treatment of dementia associated with Parkinson's disease and AIDS Dementia Complex, however, development has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
TNF-alpha 17 Target ID: CHEMBL1825 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11175320 \| http://adisinsight.springer.com/drugs/800009270 \| https://www.ncbi.nlm.nih.gov/pubmed/12528314	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Sciatica 2 Sources: http://adisinsight.springer.com/drugs/800009270	Primary	Phase II 1147	Unknown Approved Use Unknown
Postherpetic neuralgia 13 Sources: http://adisinsight.springer.com/drugs/800009270	Primary	Phase II 1147	Unknown Approved Use Unknown
AIDS dementia complex 1 Sources: http://adisinsight.springer.com/drugs/800009270 https://www.ncbi.nlm.nih.gov/pubmed/9622673	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
26 μg/mL EXPERIMENT https://thescipub.com/pdf/ajptsp.2007.30.38.pdf	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		CP1-1189 plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
413 μg × h/mL EXPERIMENT https://thescipub.com/pdf/ajptsp.2007.30.38.pdf	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		CP1-1189 plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.9 h EXPERIMENT https://thescipub.com/pdf/ajptsp.2007.30.38.pdf	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		CP1-1189 plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=124950175	no

Sourcing

Vendor/Aggregator	ID	URL
AChemBlock	O33685	http://www.achemblock.com/catalogsearch/result/?q=O33685
ApexBio Technology	B6109	https://www.apexbt.com/catalogsearch/result/?q=B6109
Aronis	e00311	http://www.aronis.ru/store/index.php?main_page=advanced_search_result&search_in_description=1&keyword=e00311
Aronis	RESYN/84569	http://www.aronis.ru/store/index.php?main_page=advanced_search_result&search_in_description=1&keyword=RESYN/84569
AstaTech	44169	http://astatechinc.com/CPSResult.php?CRNO=44169
ChemBridge	5736403	http://www.hit2lead.com/screening-compounds/5736403
ChemDiv	Y030-2548	http://chemistryondemand.com:8080/eShop/search_results.jsp?idnumber=Y030-2548
ChemShuttle	153193	https://www.chemshuttle.com/catalogsearch/result/?q=153193
Chemspace	CSC000387519	https://chem-space.com/CSC000387519
eMolecules	3966036	https://orderbb.emolecules.com/search/#?query=3966036
Enamine	BBV-39257876	http://www.enaminestore.com/catalog/BBV-39257876
Enamine	Z54894388	https://www.enaminestore.com/catalog/Z54894388
KeyOrganics	AS-35332	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-35332
Lab Network	LN02086010	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN02086010
mcule	MCULE-4343710932	https://mcule.com/MCULE-4343710932/
Molnova	M17393	https://www.molnova.com/en/serch-list.html?keywords=M17393
MolPort	MolPort-001-508-343	https://www.molport.com/shop/molecule-link/MolPort-001-508-343
MuseChem	I009006	https://www.musechem.com/product/I009006.html
Otava	4584670	https://search.otavachemicals.com/#!/search?query=4584670&type=code
Princeton BioMolecular Research	OSSK_382614	http://www.princetonbio.com/order_online?common_id=OSSK_382614
ShangHai Biochempartner	BCP20741	http://www.biochempartner.com/search_BCP20741
TargetMol	T3561	https://www.targetmol.com/search?keyword=T3561
Vitas-M Laboratory	STK087738	http://www.vitasmlab.biz/search/STK087738

PubMed

Title	Date	PubMed
A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.	2002-11-26	12451199
CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex.	2000-12	11175320
CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties?	2000-03-10	10704772

Patents

Sample Use Guides

In Vivo Use Guide

Sixty-four subjects with mild to moderate HIV-associated cognitive-motor impairment were randomized to receive either placebo or 50 or 100 mg daily of CPI-1189 in addition to optimal HIV therapy.

Route of Administration: Oral

In Vitro Use Guide

CPI-1189 inhibits p38-MAPK phosphorylation at concentrations of 10 nM or less.

Name

Type

Language

CP1-1189

Common Name

English

CPI-1189

Preferred Name

English

BENZAMIDE, 4-(ACETYLAMINO)-N-(1,1-DIMETHYLETHYL)-

Systematic Name

English

Code System Code Type Description

CAS

183619-38-7